Fidelion Diagnostics Partnership: BioNexus Gene Lab Corp. Secures Exclusive Southeast Asian Rights for VitaGuard™ and 15% Equity Stake
ByAinvest
Wednesday, Dec 3, 2025 8:49 am ET1min read
BGLC--
BioNexus Gene Lab Corp. completed a strategic investment in Fidelion Diagnostics, acquiring a 15% equity stake in the AI-oncology platform and securing exclusive rights to VitaGuard™ across Southeast Asia. The deal positions BGLC for long-term growth in precision oncology adoption in the region. The transaction was structured to maximize balance-sheet strength and minimize dilution, with a dual-asset value creation model combining a commercial asset and an investment asset.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet